Nathalie Adda

TL;DR: Telaprevir with peginterferon-ribavirin was associated with significantly improved rates of sustained virologic response in patients with HCV genotype 1 infection who had not received previous treatment, with only 24 weeks of therapy administered in the majority of patients.

TL;DR: Among patients with chronic HCV infection who had not received treatment previously, a regimen of peginterferon-ribavirin for 24 weeks, with telaprevir for the first 12 weeks, was noninferior to the same regimen for 48 weeks in patients with undetectable HCV RNA at weeks 4 and 12, with an extended rapid virologic response achieved in nearly two thirds of patients.

TL;DR: In HCV-infected patients in whom initial peginterferon alfa-2a and ribavirin treatment failed, retreatment with telaprevir in combination with pegin terferonAlfa-1a and 2a and Ribavirin was more effective than retreatment without combination.

TL;DR: In this article, a small randomized trial of patients with both genotype 1 hepatitis C virus and HIV, adding telaprevir to peginterferon-α 2a (PEG-IFN-α2a) therapy produced a greater sustained virolo...

TL;DR: After failure to achieve SVR with TVR-based treatment, resistant variants are observed in most patients, however, presumably due to the lower fitness of those variants, they tend to be replaced with wild-type virus over time.